【摘要】 结合我国子宫颈上皮内病变和子宫颈癌发病情况，以及全球筛查策略，为实现消除子宫颈癌的目标，我国七个学（协）会专家共同制定了子宫颈癌筛查指南。本指南推荐高危型HPV核酸检测作为子宫颈癌的初筛方法，并采用经国内外权威机构认可、经临床验证可用于初筛的HPV核酸检测方法和试剂。子宫颈细胞学筛查用于不具备HPV核酸检测条件的地区，当条件成熟后，采用基于HPV核酸检测的筛查方法。联合筛查用于医疗卫生资源充足地区、机会性筛查人群以及部分特殊人群女性的子宫颈癌筛查。25岁女性为筛查起始年龄，25～64岁女性，采用每5年一次的HPV核酸单独检测/联合筛查；或每3年一次细胞学检查。65岁以上女性，如既往有充分的阴性筛查记录，可终止筛查。对不同特殊人群提出相应的筛查方案。更多还原

【Abstract】 In response to the incidence of cervical intraepithelial neoplasia and cervical cancer in China and global screening strategies, a collaborative effort was undertaken by seven Chinese medical societies to develop this guideline for cervical cancer screening. The guideline recommends high-risk human papillomavirus(hr-HPV) nucleic acid detection as the preferred method for primary screening, which should have been approved by authoritative institutions and clinically validated for primary screening. In areas without access to HPV nucleic acid testing, cytology can be used as an alternative. However, it is recommended to replace cytology with HPV-based screening as conditions permit. Cotesting(HPV testing in combination with cytology) is recommended for areas with sufficient medical resources, opportunistic screening populations, and partial special populations. The guideline recommends that individuals with a cervix initiate cervical cancer screening at age 25 years and undergo HPV testing alone or cotesting every five years, or cytology alone every three years. Women over the age of 65 who have had documented adequate negative prior screening in the past may discontinue screening. Corresponding screening programs are proposed for different special populations. The development of these guidelines is an important step in the effort to eliminate cervical cancer in China.更多还原